<SEC-DOCUMENT>0001558370-25-000715.txt : 20250207
<SEC-HEADER>0001558370-25-000715.hdr.sgml : 20250207
<ACCEPTANCE-DATETIME>20250207165256
ACCESSION NUMBER:		0001558370-25-000715
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250207
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250207
DATE AS OF CHANGE:		20250207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FENNEC PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001211583
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32295
		FILM NUMBER:		25602632

	BUSINESS ADDRESS:	
		STREET 1:		PO BOX 13628
		STREET 2:		68 TW ALEXANDER DRIVE
		CITY:			RESEARCH TRIANGLE PARK
		STATE:			NC
		ZIP:			27709
		BUSINESS PHONE:		(919) 636-4530

	MAIL ADDRESS:	
		STREET 1:		PO BOX 13628
		STREET 2:		68 TW ALEXANDER DRIVE
		CITY:			RESEARCH TRIANGLE PARK
		STATE:			NC
		ZIP:			27709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FENNEC PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20140903

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADHEREX TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20021223
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fencf-20250207x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 2/7/2025 9:35:40 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: 99ec4e1f-2523-40c6-aa3a-161e43f58759 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:fencf="http://adherex.com/20250207" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:EntityCentralIndexKey" id="Tc_NY8IvQStGUu3r-VslePNgw_1_1">0001211583</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:AmendmentFlag" id="Tc_JxWdfls8NU2zj_pjoZgbmA_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="fencf-20250207.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001211583</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-07</xbrli:startDate><xbrli:endDate>2025-02-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="filing_1"></a><a id="doc_1_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_823e5e1d_a4dc_4a88_a247_a8cc2c0a6898"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form </b><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:DocumentType" id="Narr_LSbtIUByeEyvrV2tm5r8HQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Current Report</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_ynZYkI9_f0q6BDnDlZOBOg"><b style="font-weight:bold;">February 7, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:EntityRegistrantName" id="Narr_RCfBFdJKy0Cci3DY1Asnxg"><b style="font-weight:bold;">FENNEC PHARMACEUTICALS INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:EntityFileNumber" id="Narr_uyQYQsIGBkKZ76oS2M3v-w"><b style="font-weight:bold;">001-32295</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Commission File Number)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p><a id="_708ebdf6_9201_4cd9_ad33_e4b35eaf159f"></a><a id="Tc_S1vpkztKA02twR2wNCo9PA_2_0"></a><a id="Tc_WSoVFZOER0SjjAKaCSmOww_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="Tc_OJUxVqmi8EGRGJzM2T6Ukw_1_0"><b style="font-weight:bold;">British Columbia, Canada</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:EntityTaxIdentificationNumber" id="Tc_6NF_lPth80e62TX7YXn-DQ_1_2"><b style="font-weight:bold;">20-0442384</b></ix:nonNumeric></p></td></tr><tr style="height:24.75pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(State or other jurisdiction of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">incorporation)</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><a id="_e090d7dc_684f_44cb_97fb_58d583532ff3"></a><a id="Tc_tM1A56T8sUC8_LzKXAQEKg_1_0"></a><a id="Tc_c4VCFfVZSEi4rsqefr4W5Q_2_0"></a><a id="Tc_1csC3PgVT0SFw_5ARFcWVw_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:24.75pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:EntityAddressAddressLine1" id="Narr_hF7WcctDbEC9wPnCfrtdDw"><b style="font-weight:bold;">PO Box 13628</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:EntityAddressAddressLine2" id="Narr_fZgux9dGUEOs_ffYJZZjOQ"><b style="font-weight:bold;">68 TW Alexander Drive</b></ix:nonNumeric><b style="font-weight:bold;">,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:EntityAddressCityOrTown" id="Narr_YWSH8ik4WE2YxFr9cAiS8w"><b style="font-weight:bold;">Research Triangle Park</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:EntityAddressStateOrProvince" id="Narr_U94cf_D37EiDvGvJ4XB7kg"><b style="font-weight:bold;">NC</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:EntityAddressPostalZipCode" id="Tc_weD-a_2Z_0KvTZrTWg8sew_1_2"><b style="font-weight:bold;">27709</b></ix:nonNumeric></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code:</b> (<ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:CityAreaCode" id="Narr_v6B0h1Iu8UCutFahj3iG8Q"><b style="font-weight:bold;">919</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:LocalPhoneNumber" id="Narr_2p5B6Qel10-PRUQR85gXTA"><b style="font-weight:bold;">636-4530</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_605244ff_014d_4223_aa42_d6275a578658"></a><a id="Tc_t366u-EzCEWyBqkOU--Qlg_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_BZyiYlJy0Uakl4Caz9AdAg_1_1"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_fab354cc_01e2_4748_9401_103a3c762fc2"></a><a id="Tc_atv_H9kxAUq70GeZbj4jbw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_pFnMUOcOGkiiM7eL-xtDlQ_1_1"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_bf069743_f10a_419b_8c12_d2934f366092"></a><a id="Tc_xKEwoUDiLUWkGdAG8dkf8w_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_mrD5Kb9GVUW8_jeMotMb-w_1_1"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_ba6b5d52_6143_4356_af7f_19f2aff75a6e"></a><a id="Tc_rB3Q5KkDbkGb3plUt4RamA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_WJeCHUORd0-7gr7m1VhrEw_1_1"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160; &#160; &#160; &#160; &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Securities registered pursuant to Section 12 of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2a233d4b_687d_4358_bb03_f1831b91a917"></a><div style="padding-left:0.4pt;"><a id="Tc_bEy96vxGK0K7Ded1k5r4yw_1_0"></a><a id="Tc_pDvLScRfckSZrdxCICCBAQ_1_1"></a><a id="Tc_mhTz39bmfU-2nkXiB1MAJQ_1_2"></a><a id="Tc_4QSS437ER0WAqaw0cUUaGQ_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:27.3pt;"><td style="vertical-align:bottom;width:33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;">Title of each class</p></td><td style="vertical-align:bottom;width:33.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;">Trading symbol(s)</p></td><td style="vertical-align:bottom;width:33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;">Name of each exchange on which registered</p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:bottom;width:33%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:Security12bTitle" id="Tc_IeUE7OcxlUGZUJ3lmssZ-g_2_0">Common shares, no par value</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" name="dei:TradingSymbol" id="Tc_wyPsQV3px0qKeGwGzJfatg_2_1">FENC</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;"><ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_wp5RordizUaQuWtbn53hCA">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 56.1pt 0pt 13.2pt;">Emerging growth company&#160;&#160;&#160;<ix:nonNumeric contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_sYQ29bzyU0CgwHWu5nkyUQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;</p><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;padding-bottom:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt;">&#160;</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="part_1_2_1"></a><a id="item_1_30_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_3ada91a6_6b86_450d_bad1_23c2b7e3805b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item&#160;8.01.</b></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Other Events.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27.5pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27.5pt;margin:0pt;">On February 7, 2025, Fennec Pharmaceuticals Inc. issued a news release announcing that Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, has commercially launched PEDMARQSI<sup style="font-family:'Symbol';font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#210;</sup>&#160;(sodium thiosulfate injection) in Germany. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27.5pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27.5pt;margin:0pt;">The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27.5pt;margin:0pt;">&#160;&#160;</p><a id="part_1_2_2"></a><a id="item_1_47_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27.5pt;margin:0pt;">&#160;</p><a id="_a5b22df7_3f43_413b_9f51_ce114ff19dc3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27.5pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 9.01</b></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:41.8pt;text-indent:-41.8pt;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(d)</p></td><td style="vertical-align:top;width:89.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Exhibits.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit No.</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 5.5pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 5.5pt;">&#160;</p></td></tr><tr style="height:16.65pt;"><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit 99.1</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 5.5pt;"><a style="-sec-extract:exhibit;color:auto;font-family:&quot;&quot;'Times New Roman','Times','serif'&quot;&quot;;font-size:10pt;" href="fencf-20250207xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-line:none;">Press Release dated February 7, 2025</span></a></p></td></tr><tr style="height:16.65pt;"><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit 104</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 5.5pt;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt;">&#160;</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="part_1_2_3"></a><a id="_687da915_cd8c_4c4a_9bc1_37c44f9b9515"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:27.35pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:27.5pt;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:12.4pt;"><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">FENNEC PHARMACEUTICALS INC.</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 5.5pt 0pt 5.5pt;">&#160;</p></td><td style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 5.5pt 0pt 5.5pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 5.5pt 0pt 5.5pt;">&#160;</p></td><td style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 5.5pt 0pt 5.5pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date February 7, 2025</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 5.5pt 0pt 5.5pt;">By:</p></td><td style="vertical-align:top;width:48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 5.5pt 0pt 5.5pt;">/s/ Robert Andrade</p></td></tr><tr style="height:24.75pt;"><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 5.5pt 0pt 5.5pt;">&#160;</p></td><td style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 14.3pt 0pt 14.3pt;">Robert Andrade</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 14.3pt 0pt 14.3pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fencf-20250207xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/7/2025 09:35:38 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"><img src="fencf-20250207xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:55.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:98.23pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;">FENNEC PHARMACEUTICALS ANNOUNCES COMMERCIAL LAUNCH OF PEDMARQSI</b><sup style="font-family:'Symbol';font-size:9pt;vertical-align:top;">&#210;</sup><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;"> </sup><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;">IN GERMANY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'inherit';font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">~ PEDMARQSI</i><sup style="font-family:'Symbol';font-size:9pt;vertical-align:top;"> &#210;</sup><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;"> is the First and Only Approved Therapy in the EU and</i><i style="font-size:12pt;font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">U.K.</i><i style="font-size:12pt;font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to &lt;18 Years of Age with Localized, Non-Metastatic Solid Tumors ~ </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">~ Norgine Pharmaceuticals</i><i style="font-size:12pt;font-style:italic;">&#8217;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;"> Launch of PEDMARQSI</i><sup style="font-family:'Symbol';font-size:9pt;vertical-align:top;">&#210;</sup><i style="font-size:12pt;font-style:italic;">&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">in Germany Accelerates Global Commercialization Strategy ~ </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">~ Milestone Marks an Important Step in Achieving Fennec</i><i style="font-size:12pt;font-style:italic;">&#8217;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">s Mission of Expanding Access to PEDMARQSI</i><sup style="font-family:'Symbol';font-size:9pt;vertical-align:top;">&#210;</sup><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;"> to Cancer Patients Across the Globe at Risk of Hearing Loss ~</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Research Triangle Park, NC, February 7, 2025</b><font style="font-size:12pt;">&#160;&#8211;&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, has commercially launched PEDMARQSI</font><sup style="font-family:'Symbol';font-size:9pt;vertical-align:top;">&#210;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"> (sodium thiosulfate injection) in Germany. &#160;</font><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;"> &#160;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine will commercialize</font><font style="font-size:12pt;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">PEDMARQSI</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">in</font><font style="font-size:12pt;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Europe,</font><font style="font-size:12pt;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Australia and New Zealand. Under the terms of the </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">previously announced</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"> exclusive licensing agreement with Norgine, Fennec received approximately $43 million in an upfront payment and will receive up to approximately $230 million in additional commercial and regulatory milestone payments along with double-digit tiered royalties on net sales of PEDMARQSI</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">&#210;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"> starting in the mid-teens and growing to the mid-twenties. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Until now, there have been no pharmacological interventions available to cancer patients in Germany to prevent ototoxicity, or permanent hearing loss, caused by treatment with cisplatin,</font><font style="font-size:12pt;">&#8221;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"> said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. </font><font style="font-size:12pt;">&#8220;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">We congratulate Norgine on making PEDMARQSI</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"> available to patients and healthcare providers in Germany and look forward to future launches in other major European markets.</font><font style="font-size:12pt;">&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">The </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">data from two open-label, randomized Phase 3 trials, SIOPEL 6 (pivotal) and the Clinical Oncology Group (COG) Protocol ACCL0431, demonstrated an approximate 50% reduction in the occurrence of cisplatin-induced ototoxicity in patients treated with cisplatin and sodium thiosulfate vs. those treated with cisplatin alone. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">PEDMARQSI</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity, or hearing loss, induced by cisplatin chemotherapy in patients 1 month to &lt;18 years of age with localized, non-metastatic solid tumors. PEDMARQSI was granted marketing authorization by the European Commission in June 2023 under the paediatric-use marketing authorization (PUMA), which includes 8 years plus 2 years of data and market protection.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;background:#ffffff;">About Cisplatin-Induced Ototoxicity </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">Cisplatin and other platinum compounds are essential chemotherapeutic agents for the treatment of many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity, or hearing loss, which is permanent, irreversible, and particularly harmful to the survivors of pediatric cancer.</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;background:#ffffff;"><a style="vertical-align:super;" href="#endnote-2">i</a></sup></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time.</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;background:#ffffff;"><a style="vertical-align:super;" href="#endnote-3">ii</a></sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;"> Infants and young children that are affected by ototoxicity at critical stages of development lack speech and language development and literacy, and older children and adolescents often lack social-emotional development and educational achievement.</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;background:#ffffff;"><a style="vertical-align:super;" href="#endnote-4">iii</a></sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">PEDMARK</b><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">&#160;(sodium thiosulfate injection)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">PEDMARK</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"> is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. PEDMARK is also recommended for the Adolescent and Young Adult (AYA) population by the National Comprehensive Cancer Network</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"> as a preventative treatment option to reduce hearing loss associated with platinum-based chemotherapy in patients with localized, non-metastatic tumors. PEDMARK is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the first and only therapeutic agent with proven efficacy and safety data with an established dosing regimen, across two open-label, randomized Phase 3 clinical studies, the Children&#8217;s Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. &#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">In the U.S. and Europe, it is estimated that, annually, more than 10,000 children may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult, and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;background:#ffffff;">Indications and Usage</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">PEDMARK</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;background:#ffffff;">&#174;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;"> (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Limitations of Use</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Important Safety Information &#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">episodes. Sulfite sensitivity is seen more frequently in people with asthma.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium levels at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">2</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">The most common adverse reactions (&#8805;25% with difference between arms of &gt;5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (&#8805;25% with difference between arms of &gt;5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Please see full Prescribing Information for PEDMARK</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"> at: </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">www.PEDMARK.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;background:#ffffff;">About&#160;Fennec Pharmaceuticals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"> to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;background:#ffffff;">&#210;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. For more information, please visit </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">www.fennecpharma.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Forward Looking Statements</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Except for historical information described in this press release, all other statements are forward-looking. Words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about our business strategy, timeline and other goals, plans and prospects, including our commercialization plans respecting PEDMARK</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;">/</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">PEDMARQSI</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;">, the market opportunity for and market impact of PEDMARK</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;">/ </i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;">PEDMARQSI</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;">, its potential impact on patients and anticipated benefits associated with its use, future</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;"> commercial and regulatory milestone and royalty payments from Norgine,</i><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"> </font><i style="font-size:12pt;font-style:italic;">and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company&#8217;s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company&#8217;s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company&#8217;s products will not be as large as expected, the Company&#8217;s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, our ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks </i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-size:12pt;font-style:italic;">detailed from time to time in the Company&#8217;s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2023. Fennec disclaims any obligation to update these forward-looking statements except as required by law.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;background:#ffffff;">For a more detailed discussion of related risk factors, please refer to our public filings available at&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;background:#ffffff;">www.sec.gov</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;background:#ffffff;">&#160;and&#160;</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;background:#ffffff;">www.sedar.com</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;background:#ffffff;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">PEDMARK</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;background:#ffffff;">&#174;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;"> </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">PEDMARQSI</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"> </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">and Fennec</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:top;background:#ffffff;">&#174;</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;"> are registered trademarks of Fennec Pharmaceuticals Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">&#169;2025 Fennec Pharmaceuticals Inc. All rights reserved. FEN-1604-v1</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;background:#ffffff;">For further information, please contact:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;background:#ffffff;">Investors:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Robert Andrade</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Chief Financial Officer</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">Fennec Pharmaceuticals Inc.</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">+1 919-246-5299</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;background:#ffffff;">Corporate and Media:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">Lindsay Rocco </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">Elixir Health Public Relations</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">+1 862-596-1304</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">lrocco@elixirhealthpr.com</font></p><div style="margin-bottom:5pt;margin-top:15pt;width:25%;border-bottom:1px solid black;"></div><a name="endnote-2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-family:'Calibri Light';font-size:7.5pt;vertical-align:top;">i</sup><font style="font-family:'Calibri Light';"> Rybak L. Mechanisms of Cisplatin Ototoxicity and Progress in Otoprotection. Current Opinion in Otolaryngology &amp; Head and Neck Surgery. 2007, Vol. 15: 364-369.</font></p><a name="endnote-3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-family:'Calibri Light';font-size:7.5pt;vertical-align:top;">ii</sup><font style="font-family:'Calibri Light';"> Landier W. Ototoxicity and Cancer Therapy. </font><i style="font-family:'Calibri Light';font-style:italic;">Cancer</i><font style="font-family:'Calibri Light';">. June 2016 Vol. 122, No.11: 1647-1658</font><font style="font-family:'Calibri Light';background:#ffffff;">.</font></p><a name="endnote-4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-family:'Calibri Light';font-size:7.5pt;vertical-align:top;">iii</sup><font style="font-family:'Calibri Light';"> Bass JK, Knight KR, Yock TI, et al. Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report from the Children&#39;s Oncology Group. </font><i style="font-family:'Calibri Light';font-style:italic;">Pediatric Blood &amp; Cancer</i><font style="font-family:'Calibri Light';">. 2016 Jul;63(7):1152-1162</font><font style="font-family:'Calibri Light';background:#ffffff;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>fencf-20250207xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fencf-20250207xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !* (,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "F
MNZQJ68A5 R2>U.KYT_:!^,)N'F\)Z%,6R?+OKB(\D_\ /%2/_'OR]:\C-,SH
MY5AGB*WR75OLCULLRVMFF(5"C\WT2[L]V\.>(K7Q18/?6),EEYKQ13_PS!3M
M++[;@P![XS6K6)X*T$>%_"6DZ5@!K6V2-\=WQ\Q_%LFMNN_#NHZ,'6^*ROZ]
M3@KJFJLE2^&[MZ= HHHKH, HHHH **** "BBB@ HHHH **** "BBN*^*WQ'M
MOAQX:>[;;+J$^8[2W)^^_J?]E>I_ =ZYL1B*6$HRKUG:,5=LZ,/AZF*JQH45
M>4G9'(_'OXO_ /"(6+:'I,W_ !.KE/WDJ'FVC/?_ 'CV].OIGP3X0>'SXG^)
M&B6K@O&L_P!IE)YRL?SG/U( _&N6U/4[K6=0N+Z]F:XN[AS))*YY9C_GI7N/
M[*&@&;5]:UEU^6");6-CW+'<V/H%7_OJOP^&,J\29W1Y_@3T7:*U?S=M?^&/
MVN>#I<.9+5Y/C:U?>3T7R5]/^'/I6EHHK]Y/PP**** "BBB@ HHHH **** "
MBBB@ HHHH *^'?BGXYN/'OC"\OI&86L;&&UB/1(P>./4]3]?:ON*OBKXU>#7
M\&>/K^%4VV5VQN[8CIM8DE?^ MD?0#UK\VXY5=X*FX/W.;WOT^6_SL?HO!+H
M?7*BFO?Y?=_7Y[?*YPE?8O[//A_^POAC82.FV:_=[Q_<-PO_ (ZJG\:^0]+T
MZ;6-3M+"W&9[J9(8Q_M,P _G7K?C/XU^(O"GBV\TCP_J"0Z-IA6RAMWMXW'[
MM0C<E<_>4]Z^'X:QF'RJI/'XE-K2*M:]WJWJULE^)]MQ'A,1FD(8##-)ZR=^
MRT2T3W;_  /JRDS7C_P?^/4?CN\71]7@BLM7928I(B1%<8&2 #RK8YQDYP?I
M5'Q!\+M0\7?''5]5GT_19M(ALM-"2ZYI+WA<J]P9%MW$J"-@-N20W)0XXY_>
M,LQ>%S6B\11J>[Z:WTTMWU_I'X3FN&Q>5550JTKS;[Z6LW>_;3]-SV[(]:,B
MOD33/ 6HOX-\763^'W&N7=K>Q(8O"UQ;7;%KC/-^7*RY3L%&<C!XYWOB+X*^
M(D4%[H=R+CQ1IT/A_5HM.U6V0^>=\4<<=O.!]Z7"!M_\9=N!MKZ#ZC#GY?:K
MKNK;=OZ]+GS2S2IR<_L7LMG?=[/33^KV/IW(]:,CUKY4^(G@;QNG]MZ-/9W>
MNZ;9:99V^GZGY#W;74 U.WD*31*09)(XT<, 075<Y!8XV;;PO;Q6GAIM2\+3
M:IX/MY[W^TM+TOPQ/8(UTRP_9YY+!F=YD55E7<-PW,IQ\O$_4H<JE[2]^R\K
M]]WM;N7_ &E4YW!TK6MN[=;/ILMVU=6U/I+(]:,UYW%HL-YX/\+6NE>'I+.P
MCNV9=+UA#^ZBV38\Q27*C)4J#TRHPN,"?2O"^M:-K5P+&YLK2*2WWE#9.]O&
M3(Q\N("1=N!R>N2Q.%SBN%TXJ_O?U\KGHJO-V]R][;>GG8[W-&17EUOI?B.7
M3M&NH]/0RZ'8VRQ)-,\,DDWEHT^U-C [D_=#+#!,GL:GLO#EX-0L[U[&WA@F
MU6XE>ZALF6^C'GNT>Y\YV.,*QQPK 8P2RTZ*7VB5B9/:#_KY?UN>E9'K1FO*
M])\*ZKI7ACPT;E[B>STS[+-!9(CF:,X7S!(.K;/F"CL&P02H-:OA^+7/#^KQ
MWNH:?O36& NQ9S-.T4Y?Y&9=BA46,E&;)XBC^M#I+7EE<<<1)VYH-?U_G_F>
M@4445S':%>;?'7X>?\)UX0=[6+?JNGYGML#EQCYX_P 0./<"O2:*X\9A:>.P
M\\-67NR5O^#\MSKPF*J8*O#$4G[T7?\ KUV/BGX-VZ1>+I-8G7=;:':3:C(#
MW**0@^NYE_*N)N+B2[N)9Y6+RRL7=CW).2:^A?C7X9L?AWHGB.\L"$E\3W,$
M0A48\H*6DEQ[,0OYUSWPT_9PU#Q+%%J'B!Y-)T]L,ELH_P!(E'OG[@^H)]AU
MK\*Q&28SVD,JH1YI1O*3Z*[LFWT]V*?S[G[?A\ZPGLYYI7ERQE:,5U=E=I+K
M[TFOEV/*8_$5];R:9+ \=M/IW-O-!"B.#NW LP&6(/\ >S7M/PM^.'CCQ'XA
MLM):UM]:CD=1-,T)C:),\N67"@ 9ZCGI7L6C?!WP;H<*QP>'[.8@<R7<8G<G
MUR^?TKJK'3+32X?)L[6&UB_N01A%_("OM<JX8S'!5%4EB^5:74;N]NFNFVE[
M'QN:<2Y?C:;IQPO,];.5E:_737?6URQ2T45^F'YN%%%% !1110 4444 %%%%
M !1110 4444 <_J_@^TU[Q+IVIZA&MS'IT;&UB<Y596(W.5Q@D!5QZ<\=#6^
M.*6BLH4H4W*45K)W?GT_+0TG4G-1C)Z1T7EU_/4****U,PHHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>fencf-20250207.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/7/2025 9:35:46 PM-->
<!--Modified on: 2/7/2025 9:35:46 PM-->
<xsd:schema targetNamespace="http://adherex.com/20250207" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:rxp="http://xbrl.sec.gov/rxp/2024" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:fencf="http://adherex.com/20250207">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://adherex.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="fencf-20250207_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="fencf-20250207_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>fencf-20250207_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/7/2025 9:35:46 PM-->
<!--Modified on: 2/7/2025 9:35:46 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>fencf-20250207_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/7/2025 9:35:46 PM-->
<!--Modified on: 2/7/2025 9:35:46 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="fencf-20250207.xsd#DocumentDocumentAndEntityInformation" roleURI="http://adherex.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://adherex.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638745609465019898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638745609465019898" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638745609465019898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638745609465019898" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638745609465019898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638745609465019898" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638745609465019898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638745609465019898" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638745609465019898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638745609465019898" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638745609465019898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638745609465019898" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638745609465029857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638745609465029857" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638745609465029857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638745609465029857" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638745609465029857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638745609465029857" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638745609465029857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638745609465029857" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638745609465029857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638745609465029857" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638745609465029857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638745609465029857" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638745609465029857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638745609465029857" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638745609465029857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638745609465029857" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638745609465039861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638745609465039861" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638745609465039861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638745609465039861" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638745609465039861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638745609465039861" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638745609465039861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638745609465039861" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638745609465039861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638745609465039861" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638745609465039861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638745609465039861" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638745609465039861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638745609465039861" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638745609465039861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638745609465039861" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638745609465049846" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638745609465049846" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45729872048000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  07,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-32295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FENNEC PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0442384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">PO Box 13628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">68 TW Alexander Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Research Triangle Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">636-4530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares, no par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FENC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001211583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MF ?@_DI*_=$P6_+R'Y71/U!+ P04    " ";AD=:GZ ;\+$"  #B#   #0
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " ";AD=:!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )N&
M1UKB^3F:[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( )N&1UJ97)PC$ 8  )PG   3              "
M <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ FX9'6O=\CBAT
M!   71$  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( )N&1UJ?H!OPL0(  .(,   -              "
M ;@,  !X;"]S='EL97,N>&UL4$L! A0#%     @ FX9'6I>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  !@4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fencf-20250207x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adherex.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>fencf-20250207.xsd</File>
    <File>fencf-20250207_lab.xml</File>
    <File>fencf-20250207_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="fencf-20250207x8k.htm">fencf-20250207x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "fencf-20250207x8k.htm": {
   "nsprefix": "fencf",
   "nsuri": "http://adherex.com/20250207",
   "dts": {
    "schema": {
     "local": [
      "fencf-20250207.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "fencf-20250207_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fencf-20250207_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "fencf-20250207x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://adherex.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fencf-20250207x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fencf-20250207x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-25-000715-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-000715-xbrl.zip
M4$L#!!0    ( )N&1UIS'%K_E ,  ,D,   2    9F5N8V8M,C R-3 R,#<N
M>'-DM5;;;MLX$'TOT'_@^ET7RTD*&TF*IMT"!9)VD>T">2MH:F2SE4@M2=7.
MWW=(B[)I2TI:M$]Q>&;.W&=T^7I;E>0[*,VEN)I,XW1"0#"9<[&ZFC0ZHIIQ
M/GE]_?+%Y5]1]'!S?TMRR9H*A"%, 360DPTW:_)9UC45Y Z4XF5);A3/5T#(
M-(WG<1K/2!2U'#=4HXX4Q)%E\;1#WK9\4BQ(EKQ*LC0[)_/%['QQ=D'^N>OD
M[M"]@C\EN-7Y0K,U5)08JE9@/M(*=$T97$W6QM2+)*'Y&A1L8R8KQY%FZ:L)
MH<8HOFP,O)>J>@<%;4J#N1#_-[1T=C%%)=@,! (',.94Z 4ZT%G:;#;Q9A9+
MM4)#Z31YN+O]U_GFA7.H%3 ;?J"S7:K2:\T3)4M(]I)>%\MD$=UI%E0OG99'
M;'1G7IPU2F&-'SMQ9T0#BU?R>^+10$5!,>C618)H%S,"N0F96[GS9 =VHN4@
MY2QYN.7BVT%\YK$>B,\A@;-:F:%\=%"@T!@UDG1$#QQ945KW^F&!@+7$"$8B
MM/ 21Z'SFK/^@B 0AF=J-2")R$DF!C+708$"B*;*^JJ7I0EL#0C-ER5$5@P4
M-;@S=)39G=%VEFR$44.-M0,#>P+,4^V.(ITTY4SWDSLHH,Z!]XLB$ AN3PK5
M#NIT/I\G#NTXC3K*9^ TPHF%+7T6I;-H-MT'NGK.;+=B73FV;-T?A$6"*)ZQ
MM+J>Z.V&,">:/[VZ(BZTH8+!X?#SD98_EL]'YR[?SQT[6#]A3T$1^FTW#.]=
M/Q>[]<.[E;:M^SD1"(=(?!T8-_$U7".[)1#!<GA#6#!0*G#7[H/K/4AXS AQ
MYXP*(8T;._?F7^N:BT*V3_AH6W9A^^DS-B.Q/_Z[_]!KPS7=N_:>^[]O1/ZW
M,-P\?D!653E[$\*Q>9\EV?GA/<FAX(([KU,L;$HBX@D.?U*1DQT;.:"[3(XY
MCND;_)SX)*[=;[R,&KF<IKT@K78K,J;):,F:\A<4]YX-Z[6OOB1'E?*7X!X*
MXM;-PBZ1JXGF55W:87%O:W>#7;M$OC6^8+PQ]I&7L09&YL]5^SA%K65/014[
M83G9AT@B:U"&X_G8W['D]\55TN7/QH4J4/Z9@"Z3XS%K7\)Q=,.(L4EEB#CY
MUAQ;A[O/U%O)'-F(BOVO6[N1?8JF&9Z9&$U[?\?=Z/\B>Z8#7L%:/O])FZ?G
MM\^H'A*W/VQ_G.W-[HJP8[G^ 5!+ P04    " ";AD=:[UWA<H,%  "#/@
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MF*DP(^&HZ;Q4MA@R72.*L=V:I8AI(YY,F'2K$:(!8IB&=R3\((YY>YHLZQJ
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M-<=^-7"S(>KF=XB"A3A_6'>\\0CS2'>9JY%8S*>IH<W1NU2WE#]CS*J\I2Y
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M+GAM;-5:78_B-A1]K]3_X*;/(1]\!@V[8MC9"A5VT RK7?5E91(#5A,[<LP
M_[YV$E,"R22T6B O0XB/K\\]YXZQG3Q\W 4^>$,LPI0,-*MA:@ 1EWJ8K ;:
M)M)AY&*L??SPZR\/O^GZ]\>7"?"HNPD0X<!E"'+D@2WF:S"G80@)F"+&L.^#
M1X:]%0+ ,AM.PVPT@:ZG,1YA)/I0 N)@=L,ZM(S2>)3T@6UT#=NTV\#I-]O]
M5@?,I@?<5-!;XC*@C\G???EG(08$(DT2]7<1'FAKSL.^86RWV\:VV:!L)?J;
MEO%].GEUURB .B81A\1%&A#X?A3?G% 7\EBCH^Z[!?-5@*9Q&*L0(;_I"J;+
M6[IEZTVKL8L\+:4HFRL,HN"R%;^#/\HEP9_%3S6P',<QXE9-J ?  Z,^>D%+
M$-_K\WV(!EJ$@]"7L>)[:X:6 VTIZF6I2PM,V^S*5'[_E%:(^AP2[XEPS/=C
MLJ0LB(74@!S@Z\OX0 9Z:\30KN'2P)!M1K4P<5Z5%#.2Q$*&(A$M[CX1C6DV
M<LC_S>5(*[3CB'C(.]S%7 Y@FJ9C AVH0,>7D'@@B0K^6XIQ@B)%G[H9+KZL
M7LJRQLEPD8@7QXJ0VUC1-\-#6/X[M>2%-+45&RJ^_!A1,4T,%Q%GT.4JD@\7
MR!]H)VW&S^2AU)J+B"<T3IM_=)J];JO=,9U6IVU:3L_I'9$[KH,ARQ*%S%6Q
MQ66F-,[E3Q%&")F(I[MK[!]<7S(:G.F3CD0K,J;,0TQ,SAK81(('#25CZ%])
MYQEBF(IB]SZ)R?D=P3.X>BE?3CVUP+ZN!<E<\!G[Z,LF6""6H_XII!["5V*=
M:MZ\A>8O:(4E=<*_P""OZO-@==*^ O-4_]8M]!^+-2@+*8O5>A6BH1'=$,[V
M(^H5V_%NKSJY<WDBJ5GM6Y@UA[NQ)Y(5B_)DD5PR6Q7@ZV30)2FDUG1N8<W0
M\X1N45Q"SVS&Z!M.-@/YSN3#LUG93J_=O5MC+L@@]:5[0U_2#[$+05:9*<?8
M&CI22C^UHW<?=M@7V&'7VXY\^JD=S@WM&(G+9S:G6U)FQK_(&EI10E[M_LP;
M.C&C$8?^7SA\=_F5!ZZA'^7\E257WI'+0ADR! M,.&ZNA^REC)705]YWR\->
M?[:FI'C??0JIA^"56"O1K[SQ_L8PYXB,:!!L2+JJCG*4S\750_[JU)4'YYMO
MD<L2,8:\22))(=>8:*R;[(2I&'L?'R+^5!=?J8]=S#%93<4*G&%)^<S"<U!6
MA*;3ZUAWZ%]%WLJ\\\WXG9LW8TC6)A([IOA 6CZ_8,_+9>X,6 RNAYD7\E>F
MGF_CZV7J.(HVB%UD[5F76AI<+0ME\_FIP)W;_(K<C1S)LA=S^:0Q;]H]@=3#
MQDJLE6U7/CV8,RC?E'C=!PN:]T.7::^'W.64E=97/AI0=?"T<]>0K%#!@YD\
M6#V4K\Q</8R\R8G 4X#82A3('XQN^5I,L"$D^\(C@5QT/>RX- 'ERI4/!1*:
M(Y$A@_Y8_+CM_D3%?IS@ZN1$%>K*@RN?%PS%^L*3:XS//ESE:)]ISQ)O.;U6
MYPXU+Z>LM"XZ)G@P3E^TDF_E&8DV.'EAZ<,_4$L#!!0    ( )N&1UI\#B3P
M018  &S"   5    9F5N8V8M,C R-3 R,#=X.&LN:'1M[5UK<]J^TG]_/H6>
M_.><IO/$X"O8).T98DA*[N'2M'GCD6T9'(Q-9#M /_V1? %#2&C:$&CJSC2
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MS3)BT@AO)M[SQNK[JZ?HS@5TZ-]_S<6OH-$GRA^Z)HV$>[B25I<YG#D-^42
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MZS3 6M0]<T(^>L' ^?P_4$L#!!0    ( )N&1UI&OS\1R!D  ">E   9
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M0EV)5 8<>^2Q;4YWVX66Z)_7KMN^5B$T?70SDGV9LMW=5N?URSXL>[*,209
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M9^1R34= ^W/4$':2ABUL5@E.<'"4&9T( #K?CP3K8UY'(V[Q'UXL@G6B2'>
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M[*W6(3UZ8[(AZX61C"7Y6LF?\?9-[\4L=U$(O:(8 6N%O*].A!N?I%F3+):
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MZW ,?XS22!W\/U!+ 0(4 Q0    ( )N&1UIS'%K_E ,  ,D,   2
M      "  0    !F96YC9BTR,#(U,#(P-RYX<V102P$"% ,4    " ";AD=:
M[UWA<H,%  "#/@  %@              @ '$ P  9F5N8V8M,C R-3 R,#=?
M;&%B+GAM;%!+ 0(4 Q0    ( )N&1UK5]766J00  ( H   6
M  "  7L)  !F96YC9BTR,#(U,#(P-U]P<F4N>&UL4$L! A0#%     @ FX9'
M6GP.)/!!%@  ;,(  !4              ( !6 X  &9E;F-F+3(P,C4P,C W
M>#AK+FAT;5!+ 0(4 Q0    ( )N&1UI&OS\1R!D  ">E   9
M  "  <PD  !F96YC9BTR,#(U,#(P-WAE>#DY9#$N:'1M4$L%!@     %  4
*4@$  ,L^      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>fencf-20250207x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fencf-20250207.xsd" xlink:type="simple"/>
    <context id="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001211583</identifier>
        </entity>
        <period>
            <startDate>2025-02-07</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Tc_NY8IvQStGUu3r-VslePNgw_1_1">0001211583</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Tc_JxWdfls8NU2zj_pjoZgbmA_2_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_LSbtIUByeEyvrV2tm5r8HQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_ynZYkI9_f0q6BDnDlZOBOg">2025-02-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_RCfBFdJKy0Cci3DY1Asnxg">FENNEC PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityFileNumber
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_uyQYQsIGBkKZ76oS2M3v-w">001-32295</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Tc_OJUxVqmi8EGRGJzM2T6Ukw_1_0">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Tc_6NF_lPth80e62TX7YXn-DQ_1_2">20-0442384</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_hF7WcctDbEC9wPnCfrtdDw">PO Box 13628</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_fZgux9dGUEOs_ffYJZZjOQ">68 TW Alexander Drive</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_YWSH8ik4WE2YxFr9cAiS8w">Research Triangle Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_U94cf_D37EiDvGvJ4XB7kg">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Tc_weD-a_2Z_0KvTZrTWg8sew_1_2">27709</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_v6B0h1Iu8UCutFahj3iG8Q">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_2p5B6Qel10-PRUQR85gXTA">636-4530</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Tc_BZyiYlJy0Uakl4Caz9AdAg_1_1">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Tc_pFnMUOcOGkiiM7eL-xtDlQ_1_1">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Tc_mrD5Kb9GVUW8_jeMotMb-w_1_1">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Tc_WJeCHUORd0-7gr7m1VhrEw_1_1">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Tc_IeUE7OcxlUGZUJ3lmssZ-g_2_0">Common shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Tc_wyPsQV3px0qKeGwGzJfatg_2_1">FENC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_wp5RordizUaQuWtbn53hCA">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_2_7_2025_To_2_7_2025_5eEgRBDYHE26mjqFlVX9CQ"
      id="Narr_sYQ29bzyU0CgwHWu5nkyUQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
